Mirjam C Boelens
Overview
Explore the profile of Mirjam C Boelens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
881
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Wel J, Boelens M, Jebbink M, Smulders S, Maas K, Luitse M, et al.
Neuro Oncol
. 2024 Aug;
26(12):2316-2327.
PMID: 39110039
Background: Diagnosis and treatment of leptomeningeal metastases (LM) in epidermal growth factor receptor mutation-positive (EGFRm +) non-small-cell lung carcinoma (NSCLC) is challenging. We aimed to identify resistance mechanisms (RM) to...
2.
van der Sluis K, van Sandick J, Vollebergh M, van Dieren J, Hugen N, Hartemink K, et al.
Oncogene
. 2024 Apr;
43(24):1877-1882.
PMID: 38654110
Detection of peritoneal dissemination (PD) in gastric cancer (GC) patients remains challenging. The feasibility of tumor-guided cell-free DNA (cfDNA) detection in prospectively collected peritoneal fluid (ascites and peritoneal lavage) was...
3.
Samsom K, Bosch L, Schipper L, Schout D, Roepman P, Boelens M, et al.
Nat Protoc
. 2023 Dec;
19(3):700-726.
PMID: 38092944
Two decades after the genomics revolution, oncology is rapidly transforming into a genome-driven discipline, yet routine cancer diagnostics is still mainly microscopy based, except for tumor type-specific predictive molecular tests....
4.
Koster R, Schipper L, Giesbertz N, van Beek D, Mendeville M, Samsom K, et al.
Genet Med
. 2023 Nov;
26(2):101032.
PMID: 38006283
Purpose: Genome sequencing (GS) enables comprehensive molecular analysis of tumors and identification of hereditary cancer predisposition. According to guidelines, directly determining pathogenic germline variants (PGVs) requires pretest genetic counseling, which...
5.
Wessels P, Boelens M, Monkhorst K, Sonke G, van den Broek D, Brandsma D
J Neurooncol
. 2023 Feb;
162(1):1-13.
PMID: 36820955
Acquired mutations or altered gene expression patterns in brain metastases (BM) and/or leptomeningeal metastases (LM) of breast cancer may play a role in therapy-resistance and offer new molecular targets and...
6.
Houthuijzen J, de Bruijn R, van der Burg E, Drenth A, Wientjens E, Filipovic T, et al.
Nat Commun
. 2023 Jan;
14(1):183.
PMID: 36635273
Cancer-associated fibroblasts (CAFs) are abundantly present in the microenvironment of virtually all tumors and strongly impact tumor progression. Despite increasing insight into their function and heterogeneity, little is known regarding...
7.
Hondelink L, Jebbink M, von der Thusen J, Cohen D, Dubbink H, Paats M, et al.
JTO Clin Res Rep
. 2021 Dec;
2(12):100252.
PMID: 34849493
Introduction: With the approval of first-line osimertinib treatment in stage IV EGFR-mutated NSCLC, detection of resistance mechanisms will become increasingly important-and complex. Clear guidelines for analyses of these resistance mechanisms...
8.
Roepman P, de Bruijn E, van Lieshout S, Schoenmaker L, Boelens M, Dubbink H, et al.
J Mol Diagn
. 2021 May;
23(7):816-833.
PMID: 33964451
Whole genome sequencing (WGS) using fresh-frozen tissue and matched blood samples from cancer patients may become the most complete genetic tumor test. With the increasing availability of small biopsies and...
9.
Radonic T, Geurts-Giele W, Samsom K, Roemen G, von der Thusen J, Thunnissen E, et al.
J Thorac Oncol
. 2021 Feb;
16(5):798-806.
PMID: 33588111
Introduction: RET gene fusions are established oncogenic drivers in 1% of NSCLC. Accurate detection of advanced patients with RET fusions is essential to ensure optimal therapy choice. We investigated the...
10.
Huijberts S, Boelens M, Bernards R, Opdam F
Br J Cancer
. 2020 Nov;
124(1):176-182.
PMID: 33204026
Background: Treatment strategies inhibiting BRAF in combination with EGFR have been developed in patients with BRAF mutant metastatic colorectal cancer, but intrinsic and secondary resistance remains a challenge. We aimed...